Navigation Links
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Date:7/21/2008

LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia) announced today that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and moved into their new laboratory and office facilities on July 1. The Zenobia team are leaders in the areas of high-throughput structural biology and fragment-based lead discovery (FBLD).

Zenobia will focus on limited population diseases that are traditionally not pursued by larger companies. Zenobia combines the early-stage drug discovery method of FBLD with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. "There is a niche for companies that are passionate about applying innovative approaches to diseases that are not being addressed by mainstream drug discovery organizations," says Dr. Vicki Nienaber, President and founder of Zenobia. "Our mission is to find cures for these patients by working with foundations, granting agencies and leading biologists and clinicians." Zenobia will also provide access to their technology through a limited number of collaborations and partnerships.

Vicki Nienaber is well known for her pioneering work in techniques to find potential drug molecules using fragment-based screening and structure-based drug design. Vicki has managed both drug discovery and pre-clinical development programs. She was recently the Chief Scientific Officer at ActiveSight, a division of Rigaku Americas Corporation, where she built a diverse team of protein biochemistry, X-ray crystallography and drug discovery experts. Before that, Dr. Nienaber was the Senior Director of Lead Discovery and Crystallography at SGX Pharmaceuticals, where she oversaw strategic drug discovery and structural biology alliances with Novartis and Eli Lilly and initiated their internal kinase lead discovery project. While at Abbott Laboratories, she was the lead inventor of crystallographic fragment-based screening, co-inventor of the ACTOR robotic system for automated crystal sample handling and a leader in structure-based drug design methods.

Zenobia's 505 Coast Blvd facility is fully equipped for cloning, expression, purification and crystallization of proteins. Contracts are in place with synchrotron facilities for high-throughput data collection and Zenobia's compound library is available for screening. Drug discovery chemistry and pharmacology will be accessed through contract research organizations and consultants.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
2. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
3. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
4. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
9. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
10. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies ... will be accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a ... and tissue regeneration. , The novel method, developed by WPI faculty members Raymond ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, global ... Media Cybernetics corporate branding reflects a results-driven revitalization for a company with a ... re-branding components include a crisp, refreshed logo and a new web presence. , ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, Inc. ... today announced that its Board of Directors has approved the ... second quarter of 2016. The cash dividend ... July 29, 2016 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:5/23/2016)... Carolina (PRWEB) , ... May 23, 2016 , ... ... and building management solutions and services based in Aurora, Ohio, has broken ground ... established business in the Research Triangle Park area, this new location solidifies a ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):